Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpicilib plus letrozole versus standard neoadjuvant chemotherapy for ER-high luminal A early breast cancer
ChiCTR2400090520Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dalpiciclib and letrozole in breast cancer (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Residual cancer burden (RCB) 0-I rate. Started Oct 2024; status: recruiting.
02
Drugs
dalpiciclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400090520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090520.